Lascombe I - Search Results

1

Differential EGF action on nuclear protooncogenes in human endometrial carcinoma RL95-2 cells.

Sallot M, Ordener C, Lascombe I, Propper A, Adessi GL, Jouvenot M. Sallot M, et al. Among authors: lascombe i. Anticancer Res. 1996 Jan-Feb;16(1):401-6. Anticancer Res. 1996. PMID: 8615644

2

Comparison of the effects of epidermal growth factor and fetal calf serum in human endometrial carcinoma RL95-2 cells.

Sallot M, Lascombe I, Bermont L, Jouvenot M. Sallot M, et al. Among authors: lascombe i. Anticancer Res. 1997 Sep-Oct;17(5A):3499-504. Anticancer Res. 1997. PMID: 9413194

3

[Effects of 17 beta-estradiol and growth factors on cell proliferation and c-fos gene expression, in vitro, in endometrial cells in normal growth].

Ordener C, Lascombe I, Sallot M, Cypriani B, Adessi GL, Jouvenot M. Ordener C, et al. Among authors: lascombe i. C R Seances Soc Biol Fil. 1994;188(4):387-96. C R Seances Soc Biol Fil. 1994. PMID: 7736261 French.

4

Gene transfer into subcultured endometrial cells using lipofection.

Lascombe I, Mougin P, Vuillermoz C, Adessi GL, Jouvenot M. Lascombe I, et al. Biotechniques. 1996 Jan;20(1):88-91. doi: 10.2144/96201st03. Biotechniques. 1996. PMID: 8770411 Free article.

5

ERE environment- and cell type-specific transcriptional effects of estrogen in normal endometrial cells.

Lascombe I, Sallot M, Vuillermoz C, Weisz A, Adessi GL, Jouvenot M. Lascombe I, et al. Mol Cell Endocrinol. 1998 Apr 30;139(1-2):153-60. doi: 10.1016/s0303-7207(98)00064-1. Mol Cell Endocrinol. 1998. PMID: 9705083

6

Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells.

Fauconnet S, Lascombe I, Chabannes E, Adessi GL, Desvergne B, Wahli W, Bittard H. Fauconnet S, et al. Among authors: lascombe i. J Biol Chem. 2002 Jun 28;277(26):23534-43. doi: 10.1074/jbc.M200172200. Epub 2002 Apr 29. J Biol Chem. 2002. PMID: 11980898 Free article.

7

N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors.

Lascombe I, Clairotte A, Fauconnet S, Bernardini S, Wallerand H, Kantelip B, Bittard H. Lascombe I, et al. Clin Cancer Res. 2006 May 1;12(9):2780-7. doi: 10.1158/1078-0432.CCR-05-2387. Clin Cancer Res. 2006. PMID: 16675571 Free article.

8

A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells.

Boiteux G, Lascombe I, Roche E, Plissonnier ML, Clairotte A, Bittard H, Fauconnet S. Boiteux G, et al. Among authors: lascombe i. Int J Cancer. 2009 Apr 15;124(8):1820-8. doi: 10.1002/ijc.24112. Int J Cancer. 2009. PMID: 19115207

9

Expression analysis of VEGF-A and VEGF-B: relationship with clinicopathological parameters in bladder cancer.

Fauconnet S, Bernardini S, Lascombe I, Boiteux G, Clairotte A, Monnien F, Chabannes E, Bittard H. Fauconnet S, et al. Among authors: lascombe i. Oncol Rep. 2009 Jun;21(6):1495-504. doi: 10.3892/or_00000380. Oncol Rep. 2009. PMID: 19424629

10

The antidiabetic drug ciglitazone induces high grade bladder cancer cells apoptosis through the up-regulation of TRAIL.

Plissonnier ML, Fauconnet S, Bittard H, Lascombe I. Plissonnier ML, et al. Among authors: lascombe i. PLoS One. 2011;6(12):e28354. doi: 10.1371/journal.pone.0028354. Epub 2011 Dec 12. PLoS One. 2011. PMID: 22174792 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

22 results

Search Page

Filters